⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMRX News
Immuneering Corporation Class A Common Stock
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
globenewswire.com
IMRX
Form 8-K
sec.gov
IMRX
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
globenewswire.com
IMRX
Immuneering to Present at the Leerink Global Healthcare Conference
globenewswire.com
IMRX
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
IMRX
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
globenewswire.com
IMRX
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
globenewswire.com
IMRX
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
globenewswire.com
IMRX
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
globenewswire.com
IMRX
Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO)
businesswire.com
BCYC
IMRX